Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

Schizophrenia Research
M EerdekensErik Mannaert

Abstract

The pharmacokinetics and tolerability of long-acting risperidone (Risperdal Consta) were evaluated in a multicenter, prospective, open-label, 15-week study of 86 patients with schizophrenia. Subjects stabilized on 2, 4 or 6 mg of oral risperidone once daily for at least 4 weeks were assigned to receive i.m. injections of 25, 50 or 75 mg of risperidone, respectively, every 2 weeks for 10 weeks. The 90% confidence intervals for the i.m./oral ratios of the mean steady-state plasma-AUC, corrected for dosing interval, and of the average plasma concentration of the active moiety (risperidone plus 9-hydroxyrisperidone) were within the range of 80-125%, indicating bioequivalence of the i.m. and oral formulations. However, mean steady-state peak concentrations of the active moiety were 25-32% lower with i.m. than oral dosing (P < 0.05) and fluctuations in plasma active-moiety levels were 32-42% lower with the i.m. than oral regimen. Symptoms of schizophrenia continued to improve after switching from oral to i.m. dosing. Long-acting risperidone was well tolerated locally and systematically. Although overall bioequivalence of the two formulations was established, the differences in pharmacokinetic profiles between the two formulations ind...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jun 1, 1984·Journal of Clinical Psychopharmacology·L EreshefskyN R Burch
Jun 1, 1980·British Journal of Anaesthesia·A Schou Olesen, M S Hüttel
Aug 12, 1995·BMJ : British Medical Journal·J Hay
Apr 13, 2000·Pharmacopsychiatry·R TavcarV Zvan
Jun 5, 2003·The American Journal of Psychiatry·John M KaneKeith Karcher

❮ Previous
Next ❯

Citations

Mar 13, 2014·Journal of Drug Delivery·Susan D'SouzaPatrick P Deluca
May 28, 2010·The British Journal of Psychiatry. Supplement·W Wolfgang Fleischhacker
Jul 20, 2005·Primary Care Companion to the Journal of Clinical Psychiatry·Prakash S Masand
Feb 3, 2009·Neuropsychiatric Disease and Treatment·Michael K Rainer
Jun 30, 2009·Advances in Therapy·David E KempRoger S McIntyre
Aug 9, 2011·Neuropsychiatric Disease and Treatment·Mário Rodrigues LouzãJosé Carlos Appolinário
Jul 4, 2012·Annals of General Psychiatry·Thomas R EinarsonMichiel E H Hemels
Nov 15, 2011·Neurochemical Research·Anna Dietrich-MuszalskaJolanta Rabe-Jabłońska
Jul 31, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Susan D'SouzaPatrick DeLuca
Mar 9, 2007·Community Mental Health Journal·John P DochertyMary Kujawa
Feb 24, 2016·International Journal of Pharmaceutics·Taekun AnSung-Joo Hwang
Feb 10, 2006·Current Medical Research and Opinion·Eduard Parellada
Dec 9, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Joke MeeusGuy Van den Mooter
Apr 29, 2011·Colloids and Surfaces. B, Biointerfaces·Zhenhua HuTuo Jin
Jun 24, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·S HeresW Kissling
Jul 7, 2007·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Yaxin LuXiumei Lu
Nov 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sung-Wan KimJin-Sang Yoon
Apr 2, 2009·International Journal of Clinical Practice·D M Taylor
Mar 16, 2007·Acta Psychiatrica Scandinavica·H A Nasrallah
Jul 25, 2006·Clinical Therapeutics·Hans-Jürgen Möller
Dec 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rossella MedoriGerhard Gründer
Jun 5, 2012·International Journal of Pharmaceutics·Archana RawatDiane J Burgess
Dec 3, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Joke MeeusGuy Van den Mooter
Apr 29, 2016·Journal of Medical Economics·Thomas R EinarsonKristel van Impe
Aug 6, 2016·Pharmaceutical Development and Technology·Elham JafarifarAli Fattahi
Nov 9, 2016·International Journal of Pharmaceutics·Jinlong ZhaoYouxin Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here